Burabha Pussadhamma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Burabha Pussadhamma has a total of 366 co-authors. Here are the top co-authors by number of shared publications:
Ajanee Mahakkanukrauh
Rheumatology Unit, Department of Medicine, Faculty of Medicine, Khon Kaen University , Khon Kaen , Thailand
4 shared publicationsRatanavadee Nanagara
Division of Rheumatology, Department of Medicine, Khon Kaen University, Khon Kaen, Thailand
4 shared publicationsSiraphop Suwannaroj
Rheumatology Unit, Department of Medicine, Faculty of Medicine, Khon Kaen University , Khon Kaen , Thailand
4 shared publicationsChaiyasith Wongvipaporn
Division of Cardiology, Queen Sirikit Heart Center of the Northeast, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand
3 shared publicationsChingching Foocharoen
Rheumatology Unit, Department of Medicine, Faculty of Medicine, Khon Kaen University , Khon Kaen , Thailand
3 shared publications- Chingching Foocharoen
Department of Medicine, Faculty of Medicine, Khon Kaen University , Khon Kaen , Thailand
3 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
Serum amino acid profiles in acute myocardial infarction: NMR metabolomics comparison of STEMI, NSTEMI, and controls
Altered amino acid metabolism may reflect the acute metabolic response to atherosclerotic cardiovascular disease, but its association with acute myocardial infarction (AMI) remains unclear. This study aimed to characterize serum amino acid profiles in patients with AMI and compare non-ST-segment elevation myocardial infarction (NSTEMI) with ST-segment elevation myocardial infarction (STEMI). In this retrospective cross-sectional study, serum samples from age-comparable controls without symptoms of coronary artery disease (CAD) and 60 patients with AMI, including 35 with NSTEMI and 25 with STEMI, were analyzed using nuclear magnetic resonance (NMR) spectroscopy. Metabolic differences were evaluated using principal component analysis (PCA), orthogonal projection to latent structures discriminant analysis (O-PLS-DA), univariate testing, and logistic regression. Thirty-one serum metabolites were identified, and validated O-PLS-DA models differentiated controls, NSTEMI, and STEMI. Compared with controls, patients with AMI had significantly lower serum concentrations of isoleucine, valine, alanine, leucine, glutamine, tyrosine, histidine, and phenylalanine. All these amino acids except glutamine were also significantly lower in STEMI than in NSTEMI. Reduced isoleucine, valine, alanine, leucine, tyrosine, histidine, and phenylalanine were consistently associated with both AMI and STEMI, whereas reduced glutamine was associated with AMI only. These findings demonstrate distinct serum amino acid alterations across AMI phenotypes and support their further investigation as exploratory indicators of acute metabolic shifts. Prospective longitudinal studies are required to determine their temporal, prognostic, and mechanistic relevance.
- 10 August 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
Open AccessSerum amino acid profiles in acute myocardial infarction: NMR metabolomics comparison of STEMI, NSTEMI, and controls
Altered amino acid metabolism may reflect the acute metabolic response to atherosclerotic cardiovascular disease, but its association with acute myocardial infarction (AMI) remains unclear. This study aimed to characterize serum amino acid profiles in patients with AMI and compare non-ST-segment elevation myocardial infarction (NSTEMI) with ST-segment elevation myocardial infarction (STEMI). In this retrospective cross-sectional study, serum samples from age-comparable controls without symptoms of coronary artery disease (CAD) and 60 patients with AMI, including 35 with NSTEMI and 25 with STEMI, were analyzed using nuclear magnetic resonance (NMR) spectroscopy. Metabolic differences were evaluated using principal component analysis (PCA), orthogonal projection to latent structures discriminant analysis (O-PLS-DA), univariate testing, and logistic regression. Thirty-one serum metabolites were identified, and validated O-PLS-DA models differentiated controls, NSTEMI, and STEMI. Compared with controls, patients with AMI had significantly lower serum concentrations of isoleucine, valine, alanine, leucine, glutamine, tyrosine, histidine, and phenylalanine. All these amino acids except glutamine were also significantly lower in STEMI than in NSTEMI. Reduced isoleucine, valine, alanine, leucine, tyrosine, histidine, and phenylalanine were consistently associated with both AMI and STEMI, whereas reduced glutamine was associated with AMI only. These findings demonstrate distinct serum amino acid alterations across AMI phenotypes and support their further investigation as exploratory indicators of acute metabolic shifts. Prospective longitudinal studies are required to determine their temporal, prognostic, and mechanistic relevance.
- Open Access
- 20 February 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1) , 30
Validity and reliability testing of the Thai version of the emPHasis-10 questionnaire for patients with pulmonary arterial hypertension
Background: The emPHasis-10 questionnaire is a specific tool for assessing health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH). We conducted the cross-cultural validation of the Thai emPHasis-10 questionnaire with an assessment of its validity and reliability in patients with PAH. Methods: The original English emPHasis-10 questionnaire was translated into Thai using a forward and backward translation process. Content validity was assessed by five experts using the Item-Objective Congruence (IOC) index, and reliability was assessed by 20 patients with PAH using Cronbach’s alpha for internal consistency and the intraclass correlation coefficient (ICC) for test-retest reliability. All patients had a confirmed diagnosis of PAH by right heart catheterization, and baseline clinical and hemodynamic characteristics were collected. Results: For Thai emPHasis-10 questionnaire, the IOC value was 0.94 (range 0.80 to 1.00). Among all patients, 19 (95%) were female, and the mean age±standard deviation (SD) was 46.8 ± 14.2 years, and 17 (85%) were at World Health Organization functional class II. Idiopathic PAH, PAH associated with connective tissue disease, and PAH associated with congenital heart disease were classified in 7, 6, and 7 patients, respectively. The mean baseline mean pulmonary arterial pressure and pulmonary vascular resistance were 55.1 ± 19.5 mmHg and 13.1 ± 8.4 Wood units, respectively. The mean ± SD of the Thai emPHasis-10 score was 18 ± 10. Cronbach’s alpha and ICC values were 0.925 and 0.996 (95% confidence interval 0.991 to 0.999), respectively. Conclusion: The Thai emPHasis-10 questionnaire has acceptable validity and reliability. This tool can be used as an additional measure for PAH severity assessment.
- 20 February 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1) , 30
Open AccessValidity and reliability testing of the Thai version of the emPHasis-10 questionnaire for patients with pulmonary arterial hypertension
Background: The emPHasis-10 questionnaire is a specific tool for assessing health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH). We conducted the cross-cultural validation of the Thai emPHasis-10 questionnaire with an assessment of its validity and reliability in patients with PAH. Methods: The original English emPHasis-10 questionnaire was translated into Thai using a forward and backward translation process. Content validity was assessed by five experts using the Item-Objective Congruence (IOC) index, and reliability was assessed by 20 patients with PAH using Cronbach’s alpha for internal consistency and the intraclass correlation coefficient (ICC) for test-retest reliability. All patients had a confirmed diagnosis of PAH by right heart catheterization, and baseline clinical and hemodynamic characteristics were collected. Results: For Thai emPHasis-10 questionnaire, the IOC value was 0.94 (range 0.80 to 1.00). Among all patients, 19 (95%) were female, and the mean age±standard deviation (SD) was 46.8 ± 14.2 years, and 17 (85%) were at World Health Organization functional class II. Idiopathic PAH, PAH associated with connective tissue disease, and PAH associated with congenital heart disease were classified in 7, 6, and 7 patients, respectively. The mean baseline mean pulmonary arterial pressure and pulmonary vascular resistance were 55.1 ± 19.5 mmHg and 13.1 ± 8.4 Wood units, respectively. The mean ± SD of the Thai emPHasis-10 score was 18 ± 10. Cronbach’s alpha and ICC values were 0.925 and 0.996 (95% confidence interval 0.991 to 0.999), respectively. Conclusion: The Thai emPHasis-10 questionnaire has acceptable validity and reliability. This tool can be used as an additional measure for PAH severity assessment.
- Open Access
- 1 June 2024
- Published by Walter de Gruyter GmbH in Rheumatology and Immunology Research
- Vol. 5 (2) , 117-125
Outcomes of myocarditis in systemic sclerosis: A 3-year follow-up
Background and Objectives: The clinical course, the outcomes of myocarditis, and the imaging progression of cardiac magnetic resonance imaging (MRI) in systemic sclerosis (SSc) are still unknown. We aimed at defining changes in cardiac MRI findings, the clinical course, and the outcomes of SSc patients previously defined as having myocarditis by cardiac MRI. Methods: This prospective cohort study included SSc patients, who had previously been diagnosed with myocarditis through cardiac MRI at the Scleroderma Clinic of Khon Kaen University, between 2018 and 2020 and had had annual follow-ups of cardiac MRI for at least 3 years. Data on demographics, clinical characteristics, cardiac MRI findings, treatment regimens, and outcomes were collected. Serial cardiac MRI on a yearly basis was analyzed to assess changes in myocardial involvement over the 3-year period. Results: Ten SSc patients diagnosed with myocarditis via cardiac MRI were included. Most belonged to the diffuse cutaneous subset with a mean age of 58.3±8.6 years and were mildly symptomatic. Initial cardiac MRI findings showed myocardial edema and hyperemia in all patients and eight patients had had pre-existing myocardial scars, suggesting disease chronicity. Treatment for concomitant interstitial lung disease involved steroids with either cyclophosphamide or mycophenolate mofetil in 6 patients. Outcomes of myocarditis were stable, improving, and worsening in 4, 4, and 2 patients, respectively. There was no complete resolution of the cardiac MRI indices for myocarditis, and none had had major cardiac events. Conclusion: Although SSc myocarditis on cardiac MRI may improve or show stability, the changes remained persistent. Among patients with SSc and mildly symptomatic myocarditis, the efficacy of steroids and immunosuppressive therapy is inconclusive. Over a 3-year follow-up, the prognosis had been acceptably good with no cardiac events.
- 1 June 2024
- Published by Walter de Gruyter GmbH in Rheumatology and Immunology Research
- Vol. 5 (2) , 117-125
Open AccessOutcomes of myocarditis in systemic sclerosis: A 3-year follow-up
Background and Objectives: The clinical course, the outcomes of myocarditis, and the imaging progression of cardiac magnetic resonance imaging (MRI) in systemic sclerosis (SSc) are still unknown. We aimed at defining changes in cardiac MRI findings, the clinical course, and the outcomes of SSc patients previously defined as having myocarditis by cardiac MRI. Methods: This prospective cohort study included SSc patients, who had previously been diagnosed with myocarditis through cardiac MRI at the Scleroderma Clinic of Khon Kaen University, between 2018 and 2020 and had had annual follow-ups of cardiac MRI for at least 3 years. Data on demographics, clinical characteristics, cardiac MRI findings, treatment regimens, and outcomes were collected. Serial cardiac MRI on a yearly basis was analyzed to assess changes in myocardial involvement over the 3-year period. Results: Ten SSc patients diagnosed with myocarditis via cardiac MRI were included. Most belonged to the diffuse cutaneous subset with a mean age of 58.3±8.6 years and were mildly symptomatic. Initial cardiac MRI findings showed myocardial edema and hyperemia in all patients and eight patients had had pre-existing myocardial scars, suggesting disease chronicity. Treatment for concomitant interstitial lung disease involved steroids with either cyclophosphamide or mycophenolate mofetil in 6 patients. Outcomes of myocarditis were stable, improving, and worsening in 4, 4, and 2 patients, respectively. There was no complete resolution of the cardiac MRI indices for myocarditis, and none had had major cardiac events. Conclusion: Although SSc myocarditis on cardiac MRI may improve or show stability, the changes remained persistent. Among patients with SSc and mildly symptomatic myocarditis, the efficacy of steroids and immunosuppressive therapy is inconclusive. Over a 3-year follow-up, the prognosis had been acceptably good with no cardiac events.
- 27 February 2023
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 135 (4) , 410-417
The prevalence and treatment patterns of familial hypercholesterolemia among Thai patients with premature coronary artery disease
: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that is characterized by severe hypercholesterolemia. The prevalence of FH in Thailand has not been reported. Therefor...
- 27 February 2023
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 135 (4) , 410-417
The prevalence and treatment patterns of familial hypercholesterolemia among Thai patients with premature coronary artery disease
: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that is characterized by severe hypercholesterolemia. The prevalence of FH in Thailand has not been reported. Therefor...
- 1 December 2021
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 362 (6) , 570-577
Clinical Outcomes of Asymptomatic Cardiac Involvement in Systemic Sclerosis Patients After a 2-Year Follow-Up (Extended Study)
- 1 December 2021
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 362 (6) , 570-577
Clinical Outcomes of Asymptomatic Cardiac Involvement in Systemic Sclerosis Patients After a 2-Year Follow-Up (Extended Study)
- Open Access
- 29 September 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (10) , 766
Association of Major Histocompatibility Complex Class I Related Chain A/B Positive Microparticles with Acute Myocardial Infarction and Disease Severity
Background: Various cell types undergo activation and stress during atherosclerosis resulting in the development of acute myocardial infarction (AMI) in coronary artery disease (CAD). Major histocompatibility complex class I related chain A and B (MICA/B) can be expressed on the surface of activated and stressed cells and released into blood circulation in several forms including microparticles (MICA/B+ MPs) from various cell types. We aimed to investigate the association of these MICA/B+ MPs with the presence of AMI. Fifty-one AMI and 46 age-matched control subjects were recruited. Methods: Levels of MICA/B+ MPs derived from various parent cells including endothelial cells, platelets, monocytes, neutrophils, and T lymphocytes were determined by flow cytometry. Results: The levels and proportion of MICA/B+ MPs from all types of cell origin were significantly increased in AMI patients compared to those of the controls. A multivariate regression model showed an independent association between MICA/B+ MPs and AMI (OR = 11.6; 95% CI = 2.8, 47.3). Interestingly, based on the disease severity, we found that the levels of MICA/B+ MPs were significantly elevated in the ST-segment elevation myocardial infarction (STEMI) compared to the non-STEMI (NSTEMI) patients. Moreover, an independent association of MICA/B+ MPs with the occurrence of STEMI was also demonstrated (OR = 4.1; 95% CI = 1.5, 16.7). Conclusions: These results suggest that MICA/B+ MPs are associated with AMI and disease severity. They may act as mediators contributing to the pathological process of AMI. Alternatively, they are the results of various cell activations contributing to AMI.
- 29 September 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (10) , 766
Open AccessAssociation of Major Histocompatibility Complex Class I Related Chain A/B Positive Microparticles with Acute Myocardial Infarction and Disease Severity
Background: Various cell types undergo activation and stress during atherosclerosis resulting in the development of acute myocardial infarction (AMI) in coronary artery disease (CAD). Major histocompatibility complex class I related chain A and B (MICA/B) can be expressed on the surface of activated and stressed cells and released into blood circulation in several forms including microparticles (MICA/B+ MPs) from various cell types. We aimed to investigate the association of these MICA/B+ MPs with the presence of AMI. Fifty-one AMI and 46 age-matched control subjects were recruited. Methods: Levels of MICA/B+ MPs derived from various parent cells including endothelial cells, platelets, monocytes, neutrophils, and T lymphocytes were determined by flow cytometry. Results: The levels and proportion of MICA/B+ MPs from all types of cell origin were significantly increased in AMI patients compared to those of the controls. A multivariate regression model showed an independent association between MICA/B+ MPs and AMI (OR = 11.6; 95% CI = 2.8, 47.3). Interestingly, based on the disease severity, we found that the levels of MICA/B+ MPs were significantly elevated in the ST-segment elevation myocardial infarction (STEMI) compared to the non-STEMI (NSTEMI) patients. Moreover, an independent association of MICA/B+ MPs with the occurrence of STEMI was also demonstrated (OR = 4.1; 95% CI = 1.5, 16.7). Conclusions: These results suggest that MICA/B+ MPs are associated with AMI and disease severity. They may act as mediators contributing to the pathological process of AMI. Alternatively, they are the results of various cell activations contributing to AMI.
- Open Access
- 1 January 2020
- Published by SAGE Publications in Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
- Vol. 14
Correlation Between N-Terminal Pro-Brain Natriuretic Peptide Levels and Cardiopulmonary Exercise Testing in Patients With Pre-Capillary Pulmonary Hypertension: A Pilot Study
Background: N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiopulmonary exercise testing (CPET) are useful for severity assessment in patients with pulmonary hypertension (PH). Correlations between these tests in pre-capillary PH patients is less well studied.Methods: We studied 23 patients with pre-capillary PH: 8 with idiopathic pulmonary arterial hypertension (IPAH), 6 with systemic sclerosis-associated PAH (SSc-PAH), and 9 with chronic thromboembolic pulmonary hypertension (CTEPH). Clinical evaluation, NT-proBNP levels, six-minute walking test (6MWT), spirometry, and CPET were evaluated on the same day. Correlation between NT-proBNP levels and CPET parameters were investigated.Results: In all patients, NT-proBNP levels were significantly correlated with peak oxygen uptake (VO2) ( r = −0.47), peak oxygen pulse ( r = −0.43), peak cardiac output (CO) ( r = −0.57), peak end-tidal partial pressure of carbon dioxide (PETCO2) ( r = −0.74), ventilatory equivalent to carbon dioxide (VE/VCO2) at anaerobic threshold (AT) ( r = 0.73), and VE/VCO2slope ( r = 0.64). Significant correlations between NT-proBNP levels and peak PETCO2and VE/VCO2were found in IPAH and CTEPH subgroups, and a significant correlation between NT-proBNP levels and VO2at AT was found in the CTEPH subgroup. No significant correlation was found in the SSc-PAH subgroup.Conclusion: NT-proBNP levels were significantly correlated with CPET parameters in patients with IPAH and CTEPH subgroups, but not in SSc-PAH subgroup. A further study with larger population is required to confirm these preliminary findings.
- 1 January 2020
- Published by SAGE Publications in Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
- Vol. 14
Open AccessCorrelation Between N-Terminal Pro-Brain Natriuretic Peptide Levels and Cardiopulmonary Exercise Testing in Patients With Pre-Capillary Pulmonary Hypertension: A Pilot Study
Background: N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiopulmonary exercise testing (CPET) are useful for severity assessment in patients with pulmonary hypertension (PH). Correlations between these tests in pre-capillary PH patients is less well studied.Methods: We studied 23 patients with pre-capillary PH: 8 with idiopathic pulmonary arterial hypertension (IPAH), 6 with systemic sclerosis-associated PAH (SSc-PAH), and 9 with chronic thromboembolic pulmonary hypertension (CTEPH). Clinical evaluation, NT-proBNP levels, six-minute walking test (6MWT), spirometry, and CPET were evaluated on the same day. Correlation between NT-proBNP levels and CPET parameters were investigated.Results: In all patients, NT-proBNP levels were significantly correlated with peak oxygen uptake (VO2) ( r = −0.47), peak oxygen pulse ( r = −0.43), peak cardiac output (CO) ( r = −0.57), peak end-tidal partial pressure of carbon dioxide (PETCO2) ( r = −0.74), ventilatory equivalent to carbon dioxide (VE/VCO2) at anaerobic threshold (AT) ( r = 0.73), and VE/VCO2slope ( r = 0.64). Significant correlations between NT-proBNP levels and peak PETCO2and VE/VCO2were found in IPAH and CTEPH subgroups, and a significant correlation between NT-proBNP levels and VO2at AT was found in the CTEPH subgroup. No significant correlation was found in the SSc-PAH subgroup.Conclusion: NT-proBNP levels were significantly correlated with CPET parameters in patients with IPAH and CTEPH subgroups, but not in SSc-PAH subgroup. A further study with larger population is required to confirm these preliminary findings.
- 29 October 2019
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 22 (12) , 2125-2133
Clinical and laboratory predictions of myocardial inflammation as detected by cardiac magnetic resonance imaging in patients with systemic sclerosis: A pilot study
Background: Cardiac magnetic resonance imaging (cardiac MRI) has high sensitivity and specificity for differentiating cardiac fibrosis from inflammation. There is no data on the clinical and laboratory association or prediction of myocardial inflammation in systemic sclerosis—a major organ involvement in systemic sclerosis (SSc).Objectives: Our aim was to ascertain the clinical and laboratory associations with myocardial inflammation in SSc patients as detected by cardiac MRI.Methods: A cross‐sectional study was conducted among Thai adult SSc patients who had: disease onset <4 years; a New York Heart Association functional class ≥ II; and followed up at the Scleroderma Clinic, Khon Kaen University, between June 2018 and January 2019. We excluded patients who were taking steroids and/or immunosuppressants or had a diagnosed heart disease before being diagnosed with SSc. All enrolled patients underwent cardiac MRI, and clinical and laboratory assessments the same date. Myocardial inflammation was defined by cardiac MRI per the Lake Louise Criteria.Results: A total of 30 SSc patients were enrolled. The female‐to‐male ratio was 1.8:1. The majority (73%) had diffuse cutaneous SSc. The respective mean age and median duration of disease was 57 ± 8 and 2.0 years (interquartile range 1.5‐2.7). Myocardial inflammation was detected in 22 patients (73.3%). The multivariate analysis revealed that every 5 years of increased age at onset and every 5‐point increase in the modified Rodnan skin score (mRSS) at onset was significantly associated with myocardial inflammation (odds ratio 0.47, 95% CI 0.22‐0.98; and 2.64 95% CI 1.04‐6.74, respectively). Neither the SSc subset, internal organ involvement, inflammatory markers, nor cardiac and muscle enzymes were associated with myocardial inflammation in SSc.Conclusion: Myocardial inflammation is common in early‐onset SSc. An increased risk of myocardial inflammation was associated with young age and high mRSS at onset. Cardiac MRI is the suggested evaluation for high‐risk SSc patients experiencing dyspnea on exertion.
- 29 October 2019
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 22 (12) , 2125-2133
Clinical and laboratory predictions of myocardial inflammation as detected by cardiac magnetic resonance imaging in patients with systemic sclerosis: A pilot study
Background: Cardiac magnetic resonance imaging (cardiac MRI) has high sensitivity and specificity for differentiating cardiac fibrosis from inflammation. There is no data on the clinical and laboratory association or prediction of myocardial inflammation in systemic sclerosis—a major organ involvement in systemic sclerosis (SSc).Objectives: Our aim was to ascertain the clinical and laboratory associations with myocardial inflammation in SSc patients as detected by cardiac MRI.Methods: A cross‐sectional study was conducted among Thai adult SSc patients who had: disease onset <4 years; a New York Heart Association functional class ≥ II; and followed up at the Scleroderma Clinic, Khon Kaen University, between June 2018 and January 2019. We excluded patients who were taking steroids and/or immunosuppressants or had a diagnosed heart disease before being diagnosed with SSc. All enrolled patients underwent cardiac MRI, and clinical and laboratory assessments the same date. Myocardial inflammation was defined by cardiac MRI per the Lake Louise Criteria.Results: A total of 30 SSc patients were enrolled. The female‐to‐male ratio was 1.8:1. The majority (73%) had diffuse cutaneous SSc. The respective mean age and median duration of disease was 57 ± 8 and 2.0 years (interquartile range 1.5‐2.7). Myocardial inflammation was detected in 22 patients (73.3%). The multivariate analysis revealed that every 5 years of increased age at onset and every 5‐point increase in the modified Rodnan skin score (mRSS) at onset was significantly associated with myocardial inflammation (odds ratio 0.47, 95% CI 0.22‐0.98; and 2.64 95% CI 1.04‐6.74, respectively). Neither the SSc subset, internal organ involvement, inflammatory markers, nor cardiac and muscle enzymes were associated with myocardial inflammation in SSc.Conclusion: Myocardial inflammation is common in early‐onset SSc. An increased risk of myocardial inflammation was associated with young age and high mRSS at onset. Cardiac MRI is the suggested evaluation for high‐risk SSc patients experiencing dyspnea on exertion.
- Open Access
- 26 May 2017
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 73 (8) , 973-980
The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients
Purpose The aim of this study was to investigate the contributions of non-genetic and genetic factors on the variability of stable warfarin doses in Thai patients. Methods A total of 250 Thai patients with stable warfarin doses were enrolled in the study. Demographics and clinical data, e.g., age, body mass index, indications for warfarin and concomitant medications, were documented. Four single nucleotide polymorphisms in the VKORC1 − 1639G > A, CYP2C9*3, CYP4F2 rs2108622, and UGT1A1 rs887829 genes were detected from gDNA using TaqMan allelic discrimination assays. Results The patients with variant genotypes of VKORC1 − 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001). Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006). In contrast, there were no significant differences in the SWDs between the patients who carried variant alleles of CYP4F2 rs2108622 and UGT1A1 rs887829 as compared to wild-type allele carriers. Multivariate analysis, however, showed that CYP4F2 rs2108622 TT genotype accounted for a modest part of warfarin dose variability (1.2%). In contrast, VKORC1 − 1639G > A, CYP2C9*3, CYP4F2 rs2108622 genotypes and non-genetic factors accounted for 51.3% of dose variability. Conclusions VKORC1 − 1639G > A, CYP2C9*3, and CYP4F2 rs2108622 polymorphisms together with age, body mass index, antiplatelet drug use, amiodarone use, and current smoker status explained 51.3% of individual variability in stable warfarin doses. In contrast, the UGT1A1 rs887829 polymorphism did not contribute to dose variability.
- 26 May 2017
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 73 (8) , 973-980
Open AccessThe impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients
Purpose The aim of this study was to investigate the contributions of non-genetic and genetic factors on the variability of stable warfarin doses in Thai patients. Methods A total of 250 Thai patients with stable warfarin doses were enrolled in the study. Demographics and clinical data, e.g., age, body mass index, indications for warfarin and concomitant medications, were documented. Four single nucleotide polymorphisms in the VKORC1 − 1639G > A, CYP2C9*3, CYP4F2 rs2108622, and UGT1A1 rs887829 genes were detected from gDNA using TaqMan allelic discrimination assays. Results The patients with variant genotypes of VKORC1 − 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001). Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006). In contrast, there were no significant differences in the SWDs between the patients who carried variant alleles of CYP4F2 rs2108622 and UGT1A1 rs887829 as compared to wild-type allele carriers. Multivariate analysis, however, showed that CYP4F2 rs2108622 TT genotype accounted for a modest part of warfarin dose variability (1.2%). In contrast, VKORC1 − 1639G > A, CYP2C9*3, CYP4F2 rs2108622 genotypes and non-genetic factors accounted for 51.3% of dose variability. Conclusions VKORC1 − 1639G > A, CYP2C9*3, and CYP4F2 rs2108622 polymorphisms together with age, body mass index, antiplatelet drug use, amiodarone use, and current smoker status explained 51.3% of individual variability in stable warfarin doses. In contrast, the UGT1A1 rs887829 polymorphism did not contribute to dose variability.
- 14 June 2016
- Published by BMJ in Heart Asia
- Vol. 8 (2) , 13-17
Prognostic factors of in-hospital mortality in all comers with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention
Background The prognostic factors of in-hospital mortality in all comers and unselected patients with ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) have not been well established. Objective To identify the predictive factors of in-hospital mortality in patients with STEMI undergoing primary PCI in a tertiary heart centre. Methods Between January 2008 and December 2011, all patients with STEMI undergoing primary PCI were retrospectively included in this study. Baseline characteristics and angiographic data were reviewed and recorded. The study endpoint was all-cause in-hospital mortality. Results Of the 541 patients included in the study, 63 (11.6%) died during hospitalisation. Cardiogenic shock at admission was recorded in 301 patients (55.6%) and 424 patients (78%) had multivessel disease. Median door-to-device time was 65 min. After adjustment for baseline variables, the factors associated with in-hospital mortality included age >60 years (OR 2.98, 95% CI 1.17 to 7.05; p=0.01), left ventricular ejection fraction Conclusions Age, left ventricular function and final TIMI flow are significant predictors of adverse outcomes in unselected patients with STEMI undergoing primary PCI.
- 14 June 2016
- Published by BMJ in Heart Asia
- Vol. 8 (2) , 13-17
Prognostic factors of in-hospital mortality in all comers with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention
Background The prognostic factors of in-hospital mortality in all comers and unselected patients with ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) have not been well established. Objective To identify the predictive factors of in-hospital mortality in patients with STEMI undergoing primary PCI in a tertiary heart centre. Methods Between January 2008 and December 2011, all patients with STEMI undergoing primary PCI were retrospectively included in this study. Baseline characteristics and angiographic data were reviewed and recorded. The study endpoint was all-cause in-hospital mortality. Results Of the 541 patients included in the study, 63 (11.6%) died during hospitalisation. Cardiogenic shock at admission was recorded in 301 patients (55.6%) and 424 patients (78%) had multivessel disease. Median door-to-device time was 65 min. After adjustment for baseline variables, the factors associated with in-hospital mortality included age >60 years (OR 2.98, 95% CI 1.17 to 7.05; p=0.01), left ventricular ejection fraction Conclusions Age, left ventricular function and final TIMI flow are significant predictors of adverse outcomes in unselected patients with STEMI undergoing primary PCI.